Navigation Links
OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Date:4/9/2009

BOTHELL, WA, and VANCOUVER, April 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI), announced today that it has been named the 2009 Life Sciences Company of the Year by LifeSciences British Columbia. This annual award is presented by LifeSciences British Columbia to recognize a local organization that has made outstanding contributions to the development of British Columbia's life sciences industry. This award recognizes a company for execution of business strategies, scientific excellence, leadership and vision and market position/opportunity. The organization also uses this award to increase public awareness and understanding of life sciences in the province.

"We are very pleased to be recognized for this award, especially in light of what was a particularly challenging economic environment in 2008," said Scott Cormack, President and CEO of OncoGenex. "For OncoGenex, 2008 was a tremendously active year as we took measures to prepare for the final stages of clinical development of our lead product candidate, OGX-011, for the treatment of cancer. We released Phase 2 clinical data showing a survival benefit in patients treated with OGX-011 and are working closely with the FDA to develop Phase 3 study designs and protocols defining a registration path for product approval. We also took measures to extend our cash runway, and we have been advancing discussions with potential development partners."

"There is no greater honour than to be recognized by one's peers," added Cormack. "I'd like to thank all the employees at OncoGenex, as this award was earned by each and every one of them through their dedication, hard work and loyalty."

About LifeSciences British Columbia

LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, biopro
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Proove Biosciences , ... of BIO Contest for the 2015 BIO International ... 2015 BIO International Convention will take place June 15-18 ... the Buzz of BIO contest, industry leaders will be ... at the conference. The community voting period began on ...
(Date:4/16/2015)... April 16, 2015 The Council ... the prestigious 2015 Borlaug CAST Communication Award goes ... at Tuskegee University in Alabama. Award nominees must ... public presentations; and/or the use of television, radio, ... three areas. As a specialist in the field ...
(Date:4/16/2015)... ChemRar High Tech ... R&D group, and Lancet, Russian Distribution Company, ... commercialization of new medicines in ... stimulate the innovative development of the Russian ... ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , Through ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
Breaking Biology Technology:Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... 20, 2010) -- Recently, academic debate has been swirling ... the most ubiquitous of phenomena, including photosynthesis, the process ... particular, physicists have suggested that entanglement (the quantum interconnection ... atoms that are separated in physical space) could be ...
... ,, CHANTILLY, Va. , Aug. 6 ... as director of Chemical-Biological Defense Programs.  In this role, Chotani will lead ... U.S. Army and the Office of the Secretary of Defense, as well ... Health and the Centers for Disease Control. , ...
... Thursday, August 5, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA and VANCOUVER , Aug. 5 /PRNewswire-FirstCall/ - ... unaudited financial results for the three and six months ended June 30, 2010 and ... , , ...
Cached Biology Technology:TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 2TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 3OncoGenex Reports Second Quarter Financial Results 2OncoGenex Reports Second Quarter Financial Results 3OncoGenex Reports Second Quarter Financial Results 4OncoGenex Reports Second Quarter Financial Results 5OncoGenex Reports Second Quarter Financial Results 6OncoGenex Reports Second Quarter Financial Results 7OncoGenex Reports Second Quarter Financial Results 8OncoGenex Reports Second Quarter Financial Results 9
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... genes are especially challenging because they combine many ... of non-coding elements (introns). During processing, introns are ... a template for proteins called messenger RNA (mRNA). ... of a functional protein or, worse, produce an ...
... Institute of Dental and Craniofacial Research (NIDCR), part of ... new piece to the puzzle of how tumor cells ... abnormal growth, a well-known process called angiogenesis. , As ... Cell, the scientists found that in addition to the ...
... cancer that is based on infection with a specially designed ... has shown promise in clinical trials. Now, new research suggests ... as well. The study, published in the July issue of ... to viral therapy after they have been incubated at an ...
Cached Biology News:Carnegie Mellon University research reveals how cells process large genes 2Carnegie Mellon University research reveals how cells process large genes 3New lead reported in tumor angiogenesis 2New lead reported in tumor angiogenesis 3Elevated temperature enhances success of viral cancer therapy 2
...
... Product Mouse monoclonal [SPM278] ... Small cell lung carcinoma N592 live ... Cross-reacts with Human. Not yet tested in ... one of the major glycoproteins of basement ...
TLN2 Antibody...
Chicken polyclonal to Thaumatin 2 ( Abpromise for all tested applications). Antigen: Full length Thaumatin 2...
Biology Products: